IL13RA2 and glioblastoma: Different strategies to achieve this are now being investigated, e.g., pooled uni-specific CAR T cells, bi-specific CAR T cells, and tandem CAR T cells, and are showing promising results in decreasing antigen escape by tumor cells and increasing anti-tumor efficacy (77–80); for example, CAR T-cell therapy using a tandem CAR redirected against both IL13RA2 and HER2 was able to mitigate antigen escape in a murine glioblastoma model compared to uni-specific CARs (81).